Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics Inc (NASDAQ: LRMR) is a clinical-stage biotechnology company pioneering treatments for rare genetic disorders through its innovative cell-penetrating peptide platform. This page serves as your definitive source for verified updates on clinical developments, regulatory milestones, and scientific advancements.
Investors and researchers will find timely updates on key programs including CTI-1601 for Friedreich's ataxia, partnership announcements, and preclinical research breakthroughs. Our curated news collection provides essential context for understanding the company's progress in addressing complex intracellular protein deficiencies.
All content undergoes rigorous verification to ensure accuracy and relevance. You'll find press releases detailing clinical trial phases, peer-reviewed research insights, and strategic corporate updates – all organized chronologically for efficient tracking of the company's trajectory.
Bookmark this page for streamlined access to LRMR's latest developments in rare disease therapeutics. Return regularly to stay informed about critical updates that shape the company's position in the biopharmaceutical landscape.
Larimar Therapeutics (Nasdaq: LRMR) reported its Q1 2021 results, highlighting significant progress in its Phase 1 trial for Friedreich's ataxia (FA). The company has cash and investments amounting to $81.4 million as of March 31, 2021, with a net loss of $12.1 million or $0.76 per share. The increase in R&D expenses to $9.0 million reflects higher clinical costs and personnel hiring. Management announced that topline data from the Phase 1 study will be revealed on May 11, 2021, which will include crucial pharmacodynamic data.
Learmar Therapeutics, Inc. (Nasdaq: LRMR) reported its preliminary Phase 1 findings for CTI-1601, a treatment for Friedreich's ataxia, indicating safety and tolerability in doses up to 100 mg. The company holds $92.6 million in cash as of December 31, 2020, despite a net loss of $42.5 million for the year, reflecting increased R&D costs due to clinical trials and personnel. Topline data from ongoing placebo-controlled trials is anticipated in Q2 2021, alongside the initiation of new trials aimed at further advancing CTI-1601's development.
BALA CYNWYD, Pa., Feb. 18, 2021 – Larimar Therapeutics (Nasdaq: LRMR) announced that Dr. Carole Ben-Maimon, CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation is scheduled for February 26, 2021, at 8:00 AM ET, in a fireside chat format. Larimar is a clinical-stage biotech firm focused on therapies for rare diseases, notably evaluating CTI-1601 for Friedreich’s ataxia. More information can be found via their website.
Larimar Therapeutics has been added to the NASDAQ Biotechnology Index effective December 21, 2020. This index tracks biotechnology and pharmaceutical companies on the NASDAQ exchange. Larimar, focusing on treatments for complex rare diseases, is developing its lead compound, CTI-1601, for Friedreich’s ataxia. The index’s recognition may enhance visibility and potentially attract more investors to Larimar, reflecting its active involvement in the biotechnology sector.
Larimar Therapeutics (Nasdaq: LRMR) has completed dosing in its Phase 1 single ascending dose (SAD) clinical trial for CTI-1601, aimed at treating Friedreich’s ataxia (FA). Preliminary data suggests that the drug was well tolerated at doses up to 100 mg, with no serious adverse events reported. The company plans to release topline data from both the SAD and ongoing multiple ascending dose (MAD) trials in Q2 2021. CTI-1601 is designed as a frataxin replacement therapy, with potential future trials for patients under 18 years expected in the second half of 2021.
Larimar Therapeutics (Nasdaq: LRMR) announced participation in key investor events. CEO Carole Ben-Maimon will engage in virtual 1x1 meetings at Guggenheim Securities Healthcare Talks on November 16, 2020. Additionally, a pre-recorded fireside chat will be available from November 23 to December 3, 2020, at the Piper Sandler 32nd Annual Virtual Healthcare Conference, with further 1x1 meetings on December 1 and 3. Larimar focuses on treatments for rare diseases, notably evaluating CTI-1601 for Friedreich’s ataxia in a Phase 1 clinical program.
Larimar Therapeutics (Nasdaq:LRMR) reported its Q3 2020 results, showcasing progress in clinical trials and financial stability. The Phase 1 trials for CTI-1601, aimed at treating Friedreich’s ataxia, are set to deliver topline data in 1H 2021 following delays due to COVID-19. The company holds $102.3 million in cash and equivalents. Despite a net loss of $10.3 million, down from $8.6 million year-over-year, R&D expenses decreased to $6.9 million. The European Commission granted CTI-1601 orphan drug designation, enhancing regulatory support.
LARIMAR Therapeutics (Nasdaq:LRMR) announced the establishment of its Scientific Advisory Board (SAB) on October 13, 2020. The SAB includes leading experts in rare diseases and mitochondrial disorders, aiming to advance the development of CTI-1601 for Friedreich’s ataxia. The company has resumed its Phase 1 clinical trial for this treatment and received a favorable orphan drug opinion from the European Medicines Agency. The presence of distinguished advisors is expected to bolster Larimar's strategic direction in addressing complex rare disease treatment needs.
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced that CEO Carole Ben-Maimon will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020, at 1:40 p.m. EDT. The company focuses on developing treatments for complex rare diseases, with its lead compound CTI-1601 currently in Phase 1 clinical trials aimed at addressing Friedreich’s ataxia. Larimar intends to utilize its intracellular delivery platform to create additional fusion proteins targeting other rare diseases.
Larimar Therapeutics (Nasdaq:LRMR) announced that its CEO, Carole Ben-Maimon, MD, will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 17, 2020, at 11:45 a.m. EDT. A live audio webcast of the event will be available on the company's website, with an archived version available for 30 days afterward.
The company focuses on developing treatments for complex rare diseases, with its lead compound, CTI-1601, currently in a Phase 1 clinical program targeting Friedreich’s ataxia.
FAQ
What is the current stock price of Larimar Therapeutics (LRMR)?
What is the market cap of Larimar Therapeutics (LRMR)?
